Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib plus blinatumomab versus chemotherapy plus imatinib for newly diagnosed adult Philadelphia chromosome-positive acute lymphoblastic leukemia
2020-006048-15Phase 3Active
- Sponsor
- GIMEMA
- Start
- Jun 2021
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ponatinib, blinatumomab and imatinib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by GIMEMA. Primary endpoint: Event-free survival. Started Jun 2021; status: active.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2020-006048-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006048-15.